Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
69.07 USD | +0.77% |
|
-2.69% | -3.56% |
Jul. 01 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
Jul. 01 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell Midcap Growth Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.56% | 7.29B | D+ | ||
+4.65% | 96.72B | A- | ||
+5.66% | 41.43B | A- | ||
-13.20% | 32.7B | B- | ||
+79.53% | 29.06B | A | ||
-16.02% | 15.38B | C | ||
-8.17% | 12.97B | B- | ||
-13.35% | 11.36B | D+ | ||
+160.91% | 9.9B | D | ||
-56.29% | 8.79B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ITCI Stock
- Ratings Intra-Cellular Therapies, Inc.